These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21439944)

  • 1. T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice.
    Fukushima T; Nakamura A; Iwakami N; Nakada Y; Hattori H; Hoki S; Yamaguchi H; Nakagawa M; Terashima N; Narita H
    Biochem Biophys Res Commun; 2011 Apr; 407(4):730-4. PubMed ID: 21439944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.
    Lewis J; McGowan E; Rockwood J; Melrose H; Nacharaju P; Van Slegtenhorst M; Gwinn-Hardy K; Paul Murphy M; Baker M; Yu X; Duff K; Hardy J; Corral A; Lin WL; Yen SH; Dickson DW; Davies P; Hutton M
    Nat Genet; 2000 Aug; 25(4):402-5. PubMed ID: 10932182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-beta peptide (1-40) in rats.
    Nguyen PT; Kimura T; Ho SA; Tran AH; Ono T; Nishijo H
    Hippocampus; 2007; 17(6):443-55. PubMed ID: 17397046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the neurotrophic agent T-817MA on oligomeric amyloid-β-induced deficits in long-term potentiation in the hippocampal CA1 subfield.
    Takamura Y; Ono K; Matsumoto J; Yamada M; Nishijo H
    Neurobiol Aging; 2014 Mar; 35(3):532-6. PubMed ID: 24112791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
    Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
    Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons.
    Hirata K; Yamaguchi H; Takamura Y; Takagi A; Fukushima T; Iwakami N; Saitoh A; Nakagawa M; Yamada T
    J Pharmacol Exp Ther; 2005 Jul; 314(1):252-9. PubMed ID: 15798005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.
    Schindowski K; Bretteville A; Leroy K; Bégard S; Brion JP; Hamdane M; Buée L
    Am J Pathol; 2006 Aug; 169(2):599-616. PubMed ID: 16877359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain.
    Arendash GW; Lewis J; Leighty RE; McGowan E; Cracchiolo JR; Hutton M; Garcia MF
    Brain Res; 2004 Jun; 1012(1-2):29-41. PubMed ID: 15158158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration.
    Kulic L; Wollmer MA; Rhein V; Pagani L; Kuehnle K; Cattepoel S; Tracy J; Eckert A; Nitsch RM
    Neurobiol Aging; 2011 Oct; 32(10):1827-38. PubMed ID: 19942317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
    Köhler C; Bista P; Götz J; Schröder H
    Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice.
    Pennanen L; Wolfer DP; Nitsch RM; Götz J
    Genes Brain Behav; 2006 Jul; 5(5):369-79. PubMed ID: 16879631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation.
    Murakami T; Paitel E; Kawarabayashi T; Ikeda M; Chishti MA; Janus C; Matsubara E; Sasaki A; Kawarai T; Phinney AL; Harigaya Y; Horne P; Egashira N; Mishima K; Hanna A; Yang J; Iwasaki K; Takahashi M; Fujiwara M; Ishiguro K; Bergeron C; Carlson GA; Abe K; Westaway D; St George-Hyslop P; Shoji M
    Am J Pathol; 2006 Oct; 169(4):1365-75. PubMed ID: 17003492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
    Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T
    Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain.
    Lim F; Hernández F; Lucas JJ; Gómez-Ramos P; Morán MA; Avila J
    Mol Cell Neurosci; 2001 Dec; 18(6):702-14. PubMed ID: 11749044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation.
    Taniguchi T; Doe N; Matsuyama S; Kitamura Y; Mori H; Saito N; Tanaka C
    FEBS Lett; 2005 Oct; 579(25):5704-12. PubMed ID: 16219306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice.
    Pennanen L; Welzl H; D'Adamo P; Nitsch RM; Götz J
    Neurobiol Dis; 2004 Apr; 15(3):500-9. PubMed ID: 15056457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Puromycin-sensitive aminopeptidase (PSA/NPEPPS) impedes development of neuropathology in hPSA/TAU(P301L) double-transgenic mice.
    Kudo LC; Parfenova L; Ren G; Vi N; Hui M; Ma Z; Lau K; Gray M; Bardag-Gorce F; Wiedau-Pazos M; Hui KS; Karsten SL
    Hum Mol Genet; 2011 May; 20(9):1820-33. PubMed ID: 21320871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairments in impulse control in mice transgenic for the human FTDP-17 tauV337M mutation are exacerbated by age.
    Lambourne SL; Humby T; Isles AR; Emson PC; Spillantini MG; Wilkinson LS
    Hum Mol Genet; 2007 Jul; 16(14):1708-19. PubMed ID: 17517691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-817MA, a novel neurotrophic agent, ameliorates loss of GABAergic parvalbumin-positive neurons and sensorimotor gating deficits in rats transiently exposed to MK-801 in the neonatal period.
    Uehara T; Sumiyoshi T; Hattori H; Itoh H; Matsuoka T; Iwakami N; Suzuki M; Kurachi M
    J Psychiatr Res; 2012 May; 46(5):622-9. PubMed ID: 22342346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.